Tags: RockwellKent

OZEMPIC FOR ALL.

The word “Ozempic” first entered the language in 2018 when it was approved as a diabetes inhibitor. That same year, in what has to be the world’s biggest ‘off-label’ transference since the heart-disease drug Viagra became a multi-billion-dollar erectile dysfunction drug, Novo Nordisk started selling Ozempic as a weight-loss drug for very obese people.

Then in 2023, Ozempic and its fellow “GLP-1” drugs were shown to prevent strokes and heart attacks.

The next year, it made a claim to reduce kidney disease.

This year, it showed promising results in reducing the effects of Parkinson’s, as well as alcoholism and addiction, and to reduce obesity-related cancers as well.

My physician wife often says that the more unrelated diseases a drug claims to cure, the more it looks like snake oil. In the case of Ozempic, she’d be happy to be wrong. It really does look to be a universal solvent, curing most everything it touches. True, it’s so new that there hasn’t been time to understand its long-term effects. Maybe it will be the next thalidomide whose crippling effects revealed themselves not in its patients, but in their children.

Read on…

RamsayWrites

Subscribe to my Free Weekly Omnium-Gatherum Blog:

  • Every Saturday the Omnium-Gatherum blog is delivered straight to your InBox
  • Full archive
  • Posting comments and joining the community
  • First to hear about other Ramsay events and activities

Get posts directly to your inbox

This field is for validation purposes and should be left unchanged.
Name(Required)

Sign Up for Updates!

Get news from Ramsay Inc. in your inbox.

Name(Required)
Email Lists
Email Lists(Required)